Cytek Biosciences (CTKB) Cash from Operations (2020 - 2026)

Cytek Biosciences has reported Cash from Operations for 7 years, with the latest figure at 2736000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations fell 2088.8% year-over-year to 2736000.0; the trailing twelve-month figure through Mar 2026 stood at 7297000.0 (down 134.26% YoY), and the FY2025 full-year result was 4686000.0, down 118.46% from the prior year.
• Cash from Operations for Q1 2026 stood at 2736000.0, down from 771000.0 in the prior quarter.
• The five-year high for Cash from Operations was 13221000.0 in Q3 2024, with the low at 9440000.0 in Q2 2022.
• Historically, Cash from Operations has averaged 647470.59 across 5 years, with a median of 125000.0 in 2025.
• Annual changes were most pronounced in 2024 — Cash from Operations soared 411.89% — and 2026, when it tumbled 2088.8%.
• Cytek Biosciences' Cash from Operations stood at 6193000.0 in 2022, then soared by 53.59% to 9512000.0 in 2023, then sank by 79.01% to 1997000.0 in 2024, then sank by 138.61% to 771000.0 in 2025, then plunged by 254.86% to 2736000.0 in 2026.
• The last three Cash from Operations figures came in at 2736000.0 (Q1 2026), 771000.0 (Q4 2025), and 3898000.0 (Q3 2025), per Business Quant data.